Ascletis announces expansion of Ritonavir oral tablet production capacity to 530 million tablets per… EP News Bureau Mar 15, 2022 Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targetting viral proteases and a component of…
Ascletis announces signing of Ritonavir tablet purchase agreement with Phokam Pharmaceutical EP News Bureau Jan 20, 2022 Ritonavir oral tablet is a component of oral antiviral drug Paxlovid
Gannex receives US IND Approval for NASH drug candidate, an FXR agonist EP News Bureau Oct 12, 2020 In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis
